查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917745

慢性創傷護理市場－2026-2031年預測

Chronic Wound Care Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計慢性創傷護理市場將從 2025 年的 131.62 億美元成長到 2031 年的 168.94 億美元，複合年成長率為 4.25%。

慢性創傷護理市場是全球醫療設備和先進療法領域中一個重要且不斷成長的細分市場，專注於治療無法經歷正常癒合過程的傷口。這些傷口包括糖尿病足潰瘍、靜脈性腿部潰瘍、壓瘡和動脈潰瘍，由於其複雜的病理生理機制、高復發率以及與潛在疾病的關聯，造成了巨大的臨床和經濟負擔。該市場涵蓋了廣泛的產品和治療方法，從先進的傷口敷料和生物活性劑到負壓傷口治療（NPWT）設備以及新興的再生醫學解決方案。強勁的非週期性人口和流行病學趨勢是推動市場成長的根本動力。

主要市場成長要素

市場擴張受多種相互關聯的人口和疾病因素所驅動。其中一個關鍵促進因素是全球糖尿病盛行率的不斷上升。糖尿病足潰瘍（DFU）是嚴重的併發症，治療費用高昂，對患者造成很高的終生風險。神經病變、缺血和易感染病理學特徵構成了一個極具挑戰性的癒合環境，從而持續推動對專用負重裝置、抗菌敷料、生長因子和其他先進干預措施的需求，以防止病情發展至截肢。

此外，世界人口老化也進一步加劇了這個問題。老年人因活動能力下降（導致壓瘡）、組織灌注減少、靜脈功能不全等合併症發生率較高等因素，罹患慢性傷口的風險呈指數級成長。這種人口結構變化，即人口老化，與靜脈性腿部潰瘍和壓瘡的發生率直接相關，不可避免地導致需要長期、往往複雜的傷口管理的患者群體不斷擴大。

此外，多種基礎疾病的存在會顯著加重患者的負擔。慢性傷口常作為繼發性併發症出現於免疫功能、循環功能或組織完整性受損的疾病患者中，例如心血管疾病、癌症（及其治療）、自體免疫疾病和腎衰竭患者。對於患有複雜多系統疾病的患者而言，傷口管理至關重要，因此創傷護理是一項多學科協作的臨床挑戰。

主要市場限制因素

先進創傷護理產品和治療方法的高昂成本是限制市場成長和患者取得這些產品的主要因素。先進的敷料、負壓傷口治療系統、皮膚替代物和細胞療法都涉及大量的材料和技術成本。這種經濟負擔可能會限制注重成本的醫療系統採用這些產品，造成醫療服務取得的差距，並導致報銷方面的難題。為了應對這些經濟壓力，需要強力的臨床證據來證明這些先進干預措施的合理性，並展現出更優的療效，例如更快的癒合速度、更低的感染率以及因避免住院和手術而降低的長期成本。

區域展望：北美市場表現強勁

預計北美將在全球慢性創傷護理市場佔據重要佔有率。這一地位得益於多種因素的共同作用，包括完善的醫療保健基礎設施和先進醫療技術的高度普及、龐大的老齡人口和日益成長的糖尿病患病率，以及與其他許多地區相比相對有利的創新創傷護理產品報銷環境。此外，該地區還聚集了眾多領先的醫療設備和生技公司，這些公司不斷推動新解決方案的研發和商業化，進一步鞏固了主導地位。

競爭格局及創新重點

該市場構成多元化，參與者包括大規模跨國醫療設備公司、專業創傷護理公司和生物技術公司。競爭主要體現在產品有效性、臨床證據、醫護人員和患者的易用性以及強大的分銷網路等方面。策略創新主要集中在以下幾個關鍵領域：

  • 先進的生物活性敷料：開發下一代敷料，透過持續的抗菌活性、蛋白酶調節和生長因子傳遞來主動調節傷口微環境。
  • 再生醫學：細胞和組織產品（CTP）的進展，包括同種異體和自體皮膚替代物、幹細胞療法和胎盤組織基質，旨在直接促進停滯傷口的癒合。
  • 數位健康整合：將連網感測器整合到敷料和負壓傷口治療 (NPWT) 設備中，可遠端監測傷口狀況、溫度和滲出液水平，從而支援早期療育和個人化護理計劃。
  • 照護現場診斷：開發快速床邊評估傷口生物標記、細菌負荷和血流的方法，以指導有針對性的實證治療選擇。

未來展望與戰略考量

慢性創傷護理市場預計將持續成長，這主要受人口老化這一不可逆轉的趨勢以及全球糖尿病負擔日益加重的推動。未來，該市場的發展趨勢將從通用通訊協定轉向個人化傷口管理，利用診斷工具，根據患者特定的傷口病因和生物標記特徵，選擇最合適的先進治療方案。

對於行業相關人員，策略成功取決於能否產生高品質的真實世界證據，以支持基於價值的定價策略並獲得有利的報銷。為新興市場開發具有成本效益的解決方案、與綜合醫療網路和居家醫療機構建立合作關係，以及創建包含患者教育和依從性在內的綜合支持項目，將變得日益重要。隨著對基於價值的醫療保健的日益重視，能否證明產品不僅具有療效，還能改善患者的生活品質並降低整體醫療成本，將決定企業在這個重要且快速成長的治療領域中的市場領導地位。

本報告的主要優勢：

  • 深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用洞察力，做出策略決策，在動態環境中發展新的業務流和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

以下是一些公司如何使用這份報告的範例

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的實際數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區分類的收入和預測評估，包括國家/地區
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

5. 慢性創傷護理市場（按類型分類）

  • 介紹
  • 糖尿病潰瘍
  • 壓瘡
  • 靜脈潰瘍
  • 其他

6. 慢性創傷護理產品市場

  • 介紹
  • 進階傷口敷料
  • 傷口護理
  • 積極治療
  • 其他

7. 按最終使用者分類的慢性創傷護理市場

  • 介紹
  • 醫院及創傷護理中心
  • 居家醫療環境
  • 其他

8. 各地區慢性創傷護理市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Smith and Nephew
  • Cardinal Health
  • Coloplast
  • 3M
  • Tissue Regenix
  • Integra Lifesciences
  • ConvaTec Inc.
  • Molnlycke Health Care AB
  • B Braun Melsungen AG.

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061615703

The chronic wound care market is projected to expand at a 4.25% CAGR, attaining USD 16.894 billion in 2031 from USD 13.162 billion in 2025.

The chronic wound care market represents a critical and expanding segment within the global medical device and advanced therapy sector, focused on the management of wounds that fail to progress through the normal stages of healing. These wounds, which include diabetic foot ulcers, venous leg ulcers, pressure ulcers, and arterial ulcers, present a significant clinical and economic burden due to their complex pathophysiology, high recurrence rates, and association with underlying comorbidities. The market encompasses a wide range of products and therapies, from advanced wound dressings and bioactive agents to negative pressure wound therapy (NPWT) devices and emerging regenerative medicine solutions. Growth is fundamentally driven by powerful, non-cyclical demographic and epidemiological trends.

Primary Market Growth Drivers

The expansion of the market is underpinned by several powerful and interrelated demographic and disease factors. A primary driver is the global rise in the prevalence of diabetes mellitus. Diabetic foot ulcers (DFUs) are a severe and costly complication, with a high lifetime risk for patients. The pathophysiological triad of neuropathy, ischemia, and susceptibility to infection creates a challenging healing environment, driving sustained demand for specialized offloading devices, antimicrobial dressings, growth factors, and other advanced interventions aimed at preventing progression to amputation.

This is compounded by the worldwide aging of the population. Older adults are at exponentially higher risk for developing chronic wounds due to factors such as reduced mobility (leading to pressure injuries), decreased tissue perfusion, and higher rates of comorbid conditions like venous insufficiency. The demographic shift towards larger elderly populations directly correlates with increased incidence of venous leg ulcers and pressure injuries, ensuring a growing patient pool requiring long-term, often multi-modal, wound management.

Furthermore, the presence of multiple underlying systemic conditions contributes significantly to the patient burden. Chronic wounds frequently arise as secondary complications in individuals with conditions that impair immune function, circulation, or tissue integrity. This includes patients with cardiovascular diseases, cancer (and its treatments), autoimmune disorders, and renal failure. The management of these wounds is integral to the overall care of patients with complex, multi-system diseases, making wound care a cross-disciplinary clinical challenge.

Key Market Restraint

A significant constraint on market growth and patient access is the high cost associated with advanced wound care products and therapies. Advanced dressings, NPWT systems, skin substitutes, and cellular therapies involve substantial material and technology costs. This financial burden can limit adoption in cost-sensitive healthcare systems, create access disparities, and pose challenges for reimbursement. The economic pressure necessitates robust clinical evidence demonstrating that these advanced interventions lead to superior outcomes, such as faster healing times, reduced infection rates, and lower long-term costs through avoided hospitalizations and surgeries, to justify their expenditure.

Geographical Outlook: North American Market Strength

North America is expected to hold a significant share of the global chronic wound care market. This position is supported by a confluence of factors: a well-established healthcare infrastructure with high adoption rates of advanced medical technologies, a large and growing population of aging adults and individuals with diabetes, and a relatively favorable reimbursement environment for innovative wound care products compared to many other regions. Additionally, the presence of many leading medical device and biotechnology companies within the region drives continuous research, development, and commercialization of new solutions, further consolidating its market leadership.

Competitive Landscape and Innovation Focus

The market is served by a diverse group of players, including large multinational medical device corporations, specialized wound care companies, and biotechnology firms. Competition is based on product efficacy, clinical evidence, ease of use for clinicians and patients, and the strength of distributor networks. Strategic innovation is directed toward several key areas:

  • Advanced Bioactive Dressings: Development of next-generation dressings that actively modulate the wound microenvironment with sustained antimicrobial activity, protease modulation, and growth factor delivery.
  • Regenerative Medicine: Advancement of cellular and tissue-based products (CTPs), including allogeneic and autologous skin substitutes, stem cell therapies, and placental tissue matrices designed to directly stimulate healing in stalled wounds.
  • Digital Health Integration: Incorporation of connected sensors into dressings and NPWT devices to enable remote monitoring of wound status, temperature, and exudate levels, facilitating early intervention and personalized care plans.
  • Point-of-Care Diagnostics: Development of tools for rapid, bedside assessment of wound biomarkers, bacterial load, and perfusion to guide targeted, evidence-based treatment selection.

Future Trajectory and Strategic Considerations

The chronic wound care market is poised for sustained growth, driven by the irreversible demographic trends of population aging and the rising global burden of diabetes. Future evolution will be characterized by a shift from generalized protocols toward personalized wound management, leveraging diagnostic tools to select the most appropriate advanced therapy for a patient's specific wound etiology and biomarker profile.

For industry participants, strategic success will hinge on generating high-quality real-world evidence to support value-based pricing and secure favorable reimbursement. Developing cost-effective solutions for emerging markets, forging partnerships with integrated delivery networks and home health agencies, and creating comprehensive support programs that encompass patient education and adherence will be increasingly important. As the focus on value-based care intensifies, the ability to demonstrate not just product performance but also improvements in patient quality of life and reductions in total cost of care will define market leadership in this essential and growing therapeutic area.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Chronic Wound Care Market Segmentation

  • By Type
  • Diabetic Ulcers
  • Pressure Ulcers
  • Venous Ulcers
  • Others
  • By Product
  • Advanced Wound Dressings
  • Wound Care Therapy
  • Active Therapy
  • Others
  • By End-User
  • Hospitals and Wound Care Centers
  • Homecare Settings
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CHRONIC WOUND CARE MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Diabetic Ulcers
  • 5.3. Pressure Ulcers
  • 5.4. Venous Ulcers
  • 5.5. Others

6. CHRONIC WOUND CARE MARKET BY PRODUCT

  • 6.1. Introduction
  • 6.2. Advanced wound dressings
  • 6.3. Wound care therapy
  • 6.4. Active therapy
  • 6.5. Others

7. CHRONIC WOUND CARE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and wound care centers
  • 7.3. Homecare settings
  • 7.4. Others

8. CHRONIC WOUND CARE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Smith and Nephew
  • 10.2. Cardinal Health
  • 10.3. Coloplast
  • 10.4. 3M
  • 10.5. Tissue Regenix
  • 10.6. Integra Lifesciences
  • 10.7. ConvaTec Inc.
  • 10.8. Molnlycke Health Care AB
  • 10.9. B Braun Melsungen AG.

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations